Cargando…
Targeting TRAF3 Downstream Signaling Pathways in B cell Neoplasms
B cell neoplasms comprise >50% of blood cancers. However, many types of B cell malignancies remain incurable. Identification and validation of novel genetic risk factors and oncogenic signaling pathways are imperative for the development of new therapeutic strategies. We and others recently ident...
Autores principales: | Moore, Carissa R, Edwards, Shanique KE, Xie, Ping |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4422099/ https://www.ncbi.nlm.nih.gov/pubmed/25960828 http://dx.doi.org/10.4172/1948-5956.1000327 |
Ejemplares similares
-
N-benzyladriamycin-14-valerate (AD 198) exhibits potent anti-tumor activity on TRAF3-deficient mouse B lymphoma and human multiple myeloma
por: Edwards, Shanique K E, et al.
Publicado: (2013) -
Transcriptomic profiling of splenic B lymphomas spontaneously developed in B cell-specific TRAF3-deficient mice
por: Xie, Ping, et al.
Publicado: (2014) -
TRAF5 Is a Downstream Target of MAVS in Antiviral Innate Immune Signaling
por: Tang, Eric D., et al.
Publicado: (2010) -
Mutated in colorectal cancer (MCC) is a novel oncogene in B lymphocytes
por: Edwards, Shanique KE, et al.
Publicado: (2014) -
Requirement for TRAF3 in Signaling by LMP1 But Not CD40 in B Lymphocytes
por: Xie, Ping, et al.
Publicado: (2004)